AbbVie reported continued strength for Skyrizi as the IL-23 inhibitor navigates intensifying psoriasis competition. The company highlighted that quarterly Skyrizi sales reached $5.55 billion, a year-over-year and sequential increase, while projecting $21.7 billion for full-year revenue. Executives pointed to continued headroom in moderate-to-severe psoriasis and characterized share dynamics after the March approval of Icotyde, as competitors—including J&J’s Tremfya—push further into the same patient pools.